Cohance Lifesciences Ltd
COHANCE
Company Profile
Business description
Cohance Lifesciences Ltd is a CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialization. Its Business Units comprise: CDMO, API+ and Formulations, and Clinical and Analytical Services.
Contact
Hitech City Road, Panmaktha Plot, 1
202, 2nd Floor, B-Wing, Galaxy by Aurobindo Realty, Sy No 83/1
Hyderabad Knowledge City TSIIC Raidurg
Opposite IKEA
HyderabadTG500081
INDT: +91 4023549414
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
2,295
Stocks News & Analysis
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.
stocks
Bapcor is paying for the sins of its past
Shares plunged over 17% after reporting disappointing results.
stocks
Overvalued ASX share as market underestimates downside risks
Growth outlook solid, but upside more than priced in.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,390.10 | 16.40 | 0.17% |
| CAC 40 | 8,217.68 | 11.61 | 0.14% |
| DAX 40 | 24,229.46 | 29.34 | -0.12% |
| Dow JONES (US) | 46,706.58 | 515.97 | 1.12% |
| FTSE 100 | 9,423.14 | 19.57 | 0.21% |
| HKSE | 26,027.55 | 168.72 | 0.65% |
| NASDAQ | 22,990.54 | 310.57 | 1.37% |
| Nikkei 225 | 49,316.06 | 130.56 | 0.27% |
| NZX 50 Index | 13,377.85 | 32.89 | 0.25% |
| S&P 500 | 6,735.13 | 71.12 | 1.07% |
| S&P/ASX 200 | 9,094.70 | 18.80 | 0.21% |
| SSE Composite Index | 3,916.33 | 52.44 | 1.36% |